Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shakila Meshkat

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
Journal of Affective Disorders|December 5, 2024
Efficacy of orexin antagonists for the management of major depressive disorder: A systematic review of randomized clinical trialsShakila Meshkat, Angela T H Kwan, Gia Han Le, et al.
Journal of Affective Disorders|February 14, 2026
Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depressionErica S Kaczmarek, Nelson B Rodrigues, Noah Chisamore, et al.
Journal of Affective Disorders|December 15, 2022
Biomarkers of ketamine's antidepressant effect: An umbrella reviewShakila Meshkat, Roger C Ho, Bing Cao, et al.
Psychiatry Research|May 3, 2022
Sex differences in ketamine's therapeutic effects for mood disorders: A systematic reviewKatie Benitah, Ashley N Siegel, Orly Lipsitz, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|March 25, 2025
Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l'étudeNoah Chisamore, Erica S Kaczmarek, Zoe Doyle, et al.
Neuropharmacology|November 6, 2022
The therapeutic role of ketamine and esketamine in treating psychopathological domains of depressionMuhammad Youshay Jawad, Joshua D Di Vincenzo, Sebastian Badulescu, et al.
Journal of Psychopharmacology (Oxford, England)|July 1, 2025
Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depressionRyan M Brudner, Erica Kaczmarek, Marc G Blainey, et al.
Journal of Affective Disorders|April 24, 2024
Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: A systematic review and meta-analysisSabrina Wong, Gia Han Le, Lee Phan, et al.
Journal of Affective Disorders|January 20, 2024
A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic reviewSabrina Wong, Angela T H Kwan, Kayla M Teopiz, et al.
Nutrients|April 13, 2023
Indirect Calorimetry to Measure Metabolic Rate and Energy Expenditure in Psychiatric Populations: A Systematic ReviewJoshua Daniel Di Vincenzo, Liam O'Brien, Ira Jacobs, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
Journal of Affective Disorders|December 5, 2024
Efficacy of orexin antagonists for the management of major depressive disorder: A systematic review of randomized clinical trialsShakila Meshkat, Angela T H Kwan, Gia Han Le, et al.
Journal of Affective Disorders|February 14, 2026
Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depressionErica S Kaczmarek, Nelson B Rodrigues, Noah Chisamore, et al.
Journal of Affective Disorders|December 15, 2022
Biomarkers of ketamine's antidepressant effect: An umbrella reviewShakila Meshkat, Roger C Ho, Bing Cao, et al.
Psychiatry Research|May 3, 2022
Sex differences in ketamine's therapeutic effects for mood disorders: A systematic reviewKatie Benitah, Ashley N Siegel, Orly Lipsitz, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|March 25, 2025
Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l'étudeNoah Chisamore, Erica S Kaczmarek, Zoe Doyle, et al.
Neuropharmacology|November 6, 2022
The therapeutic role of ketamine and esketamine in treating psychopathological domains of depressionMuhammad Youshay Jawad, Joshua D Di Vincenzo, Sebastian Badulescu, et al.
Journal of Psychopharmacology (Oxford, England)|July 1, 2025
Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depressionRyan M Brudner, Erica Kaczmarek, Marc G Blainey, et al.
Journal of Affective Disorders|April 24, 2024
Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: A systematic review and meta-analysisSabrina Wong, Gia Han Le, Lee Phan, et al.
Journal of Affective Disorders|January 20, 2024
A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic reviewSabrina Wong, Angela T H Kwan, Kayla M Teopiz, et al.
Nutrients|April 13, 2023
Indirect Calorimetry to Measure Metabolic Rate and Energy Expenditure in Psychiatric Populations: A Systematic ReviewJoshua Daniel Di Vincenzo, Liam O'Brien, Ira Jacobs, et al.
Pageof 9